INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design
The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY™ ELLIPTA™) When Compared With Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients Within a Usual Care Setting
Sponsor: GlaxoSmithKline
A PHASE4 clinical study on Pulmonary Disease, Chronic Obstructive, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 19 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
19 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 14 earlier versions
-
Dec 2019 — Oct 2020 [monthly]
Completed PHASE4
-
Nov 2019 — Dec 2019 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Oct 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE4
-
Sep 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE4
-
Aug 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE4
-
Jul 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Jul 2019 [monthly]
Recruiting PHASE4
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE4
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE4
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE4
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE4
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE4
-
Apr 2018 — May 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .